March 08, 2023 — 04:59 pm EST

      Written by
                        RTTNews.com for                             
        




RTTNews ->


(RTTNews) - Shares of Avenue Therapeutics, Inc. (ATXI) jumped over 25% in extended session on Wednesday after the company announced that it will participate in a Type C meeting with the FDA on March 9, 2023 to discuss a proposed study protocol to assess the risk of respiratory depression related to opioid stacking on intravenous tramadol relative to an approved opioid analgesic. 
The company expects to provide an update on the outcome of the meeting in April 2023, after receipt of the meeting minutes from the FDA. 
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

© 2023, Nasdaq, Inc. All Rights Reserved.










To add symbols:


These symbols will be available throughout the site during your session.
To add symbols:


These symbols will be available throughout the site during your session.